The Tyrosine Protein Kinase Fyn pipeline drugs market research report outlays comprehensive information on the Tyrosine Protein Kinase Fyn targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Tyrosine Protein Kinase Fyn pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Oncology, Respiratory, and Infectious Disease which include the indications Parkinson’s Disease, Alzheimer’s Disease, Breast Cancer, Ovarian Cancer, Asthma, Chronic Obstructive Pulmonary Disease (COPD), Sepsis, and Coronavirus Disease 2019 (COVID-19). It also reviews key players involved in Tyrosine Protein Kinase Fyn targeted therapeutics development with respective active and dormant or discontinued products.
The Tyrosine Protein Kinase Fyn pipeline targets constitutes close to ten molecules. Out of which, approximately nine molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Filing rejected/ Withdrawn, Phase II, Preclinical, and Discovery stages are 1, 2, 4, and 2 respectively. Similarly, the universities portfolio in Discovery comprises 1 molecule.
Tyrosine Protein Kinase Fyn overview
Proto-oncogene tyrosine-protein kinase Fyn is an enzyme encoded by the FYN gene. It plays a role in many biological processes including regulation of cell growth and survival, cell adhesion, integrin-mediated signaling, cytoskeletal remodeling, cell motility, immune response and axon guidance. Inactive FYN is phosphorylated on its C-terminal tail within the catalytic domain. Following activation by PKA, the protein subsequently associates with PTK2/FAK1, allowing PTK2/FAK1 phosphorylation, activation and targeting to focal adhesions.
For a complete picture of Tyrosine Protein Kinase Fyn’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
